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Summary
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene
ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen recep-
tor (CAR)-T cell therapy, in refractory large B-cell lymphoma. To reduce
treatment-related toxicity, several exploratory safety management cohorts
were added to ZUMA-1. Specifically, cohort 6 investigated management of
cytokine release syndrome (CRS) and neurologic events (NEs) with pro-
phylactic corticosteroids and earlier corticosteroid and tocilizumab inter-
vention. CRS and NE incidence and severity were primary end-points.
Following leukapheresis, patients could receive optional bridging therapy
per investigator discretion. All patients received conditioning chemotherapy
(days !5 through !3), 2 9 106 CAR-T cells/kg (day 0) and once-daily oral
dexamethasone [10 mg, day 0 (before axi-cel) through day 2]. Forty
patients received axi-cel. CRS occurred in 80% of patients (all grade ≤2).
Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients
respectively. Sixty-eight per cent of patients did not experience CRS or NEs
within 72 h of axi-cel. With a median follow-up of 8"9 months, objective
and complete response rates were 95% and 80% respectively. Overall, pro-
phylactic corticosteroids and earlier corticosteroid and/or tocilizumab inter-
vention resulted in no grade 3 or higher CRS, a low rate of grade 3 or
higher NEs and high response rates in this study population.
Keywords: large B-cell lymphoma, axi-cel, chimaeric antigen receptor-T
cell, prophylaxis, corticosteroids, cytokine release syndrome.
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The safety and efficacy of axicabtagene ciloleucel (axi-cel), an
autologous anti-CD19 chimaeric antigen receptor (CAR)-T
cell therapy approved for treating patients with relapsed/re-
fractory (R/R) large B-cell lymphoma (LBCL) after two or
more prior lines of systemic therapy,1,2 was demonstrated in
the pivotal phase 1/2 ZUMA-1 study (NCT02348216).3,4 In
the ZUMA-1 primary analysis (median follow-up,
8"7 months), the investigator-assessed objective response rate
(ORR) was 82% and the complete response (CR) rate was
54%.4 Grade 3 or higher cytokine release syndrome (CRS)
occurred in 13 patients (13%), and grade 3 or higher neuro-
logic events (NEs) occurred in 28 patients (28%).
CRS and NEs are the adverse events (AEs) most com-
monly associated with anti-CD19 CAR-T cell therapy.5,6 CRS
is believed to result from CAR-T cell activation upon cognate
antigen recognition, causing proliferation and release of
cytokines, including interferon gamma (IFN-c) and tumour
necrosis factor a. These, in turn, activate "bystander"
immune cells (e.g. myeloid lineage immune cells), which
release inflammatory cytokines, including interleukin (IL)
6 — a key CRS mediator.7 CAR-T cell levels8 and IL-6
levels4,8,9 have been shown to correlate with CRS severity fol-
lowing CAR-T cell infusion.
Less is known regarding aetiology of NEs.6 Associations of
NEs with higher serum levels of C-reactive protein and vari-
ous cytokines have been reported.10 In ZUMA-1, elevated
levels of CAR-T cells, IL-2, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and ferritin were associated
with grade 3 or higher NEs, while levels of other biomarkers
(IL-6, IL-15, IL-2Ra) were associated with both grade 3 or
higher CRS and grade 3 or higher NEs.4
Minimising CRS and NE incidence and severity are
important goals in CAR-T therapy-related toxicity
management.11 Therefore, several exploratory safety manage-
ment cohorts were added to ZUMA-1. The cohorts were not
designed for comparative purposes and no formal hypotheses
were tested. Cohort 3 evaluated prophylactic use of the anticon-
vulsant levetiracetam starting on day 0 and the anti-IL-6 anti-
body tocilizumab on day 2.12 In cohort 3 (n = 34), relative to
cohorts 1 + 2 (n = 101), prophylactic tocilizumab appeared to
decrease rates of grade 3 or higher CRS (3% versus 13%), but
not rates of grade 3 or higher NEs (41% versus 28%).4,12 To in-
vestigate the effects of more general inflammatory suppression
on toxicities, cohort 4 (n = 41) examined use of levetiracetam
prophylaxis and earlier corticosteroid and tocilizumab inter-
vention: corticosteroids were initiated starting at grade 1 CRS
(if no improvement after 3 days) and at grade 1 NE; tocilizu-
mab was initiated at grade 1 CRS (if no improvement after
3 days), at grade 2 or higher CRS and at grade 2 or higher
NE. Rates of grade 3 or higher CRS (2%) and grade 3 or
higher NEs (17%) appeared to be lower in cohort 4 versus
cohorts 1 + 2. Importantly, no meaningful impact was
observed on CAR-T cell pharmacokinetics or investigator-
assessed disease response (73% ORR, 51% CR).13 To further
build on these findings, the impact of adding prophylactic
corticosteroids to the cohort 4 toxicity management was
assessed in cohort 6.
Patients and methods
The study protocol for phase 2 cohorts 1 + 2 of the single-
arm, multicentre, registrational ZUMA-1 study was previ-
ously described.4 Cohort 6 primarily differed from cohorts
1 + 2 in that patients received levetiracetam and corticos-
teroid prophylaxis and earlier corticosteroids and tocilizumab
for toxicity management (Fig 1). Key similarities and differ-
ences between phase 2 cohorts 1 + 2, 4 and 6 are detailed in
Table SI.
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Patients
In cohort 6, eligible patients had histologically confirmed R/
R LBCL after two or more lines of systemic therapy, were
refractory to first-line therapy [defined as best response of
progressive disease (PD) or stable disease (SD) to four or
more cycles of first-line therapy with SD duration at most
six months], or had PD or relapsed ≤12 months after autolo-
gous stem cell transplant (SCT). Additional inclusion/exclu-
sion criteria are available in Data S1. All patients provided
written informed consent. The study was approved by the
institutional review board at each site and was conducted in
accordance with the Good Clinical Practice guidelines of the
International Conference on Harmonization.
Treatment
Bridging therapy was allowed per investigator discretion (e.g.
patients with bulky or rapidly progressing disease at baseline)
after leukapheresis (Data S1). Patients received a condition-
ing regimen of cyclophosphamide (500 mg/m2/d) and flu-
darabine (30 mg/m2/d) on days ! 5 to ! 3 and 1 dose of
axi-cel (target dose, 2 9 106 CAR-T cells/kg; minimum dose,
1 9 106 CAR-T cells/kg; maximum flat dose for patients
>100 kg, 2 9 108 CAR-T cells) on day 0. Patients received
once-daily oral dexamethasone 10 mg on days 0 (before axi-
cel), 1 and 2. Starting on day 0, patients received levetirac-
etam (750 mg orally or intravenously twice daily). If no
grade 2 or higher NE occurred, the levetiracetam dose was
tapered and discontinued as clinically indicated per investiga-
tor discretion. If previously discontinued, levetiracetam was
reinitiated at the onset of subsequent grade 2 or higher NEs.
Corticosteroid therapy was used to manage all grade ≥1
NEs, all grade 2 or higher CRS and grade 1 CRS if there was
no improvement after three days (Fig 1; Table SII).
Tocilizumab was used to manage grade 2 or higher NEs with
concurrent CRS, all grade 2 or higher CRS, and grade 1 CRS
if there was no improvement after 24 h.
End-points and analyses
No formal hypothesis was tested; all end-points were ana-
lyzed descriptively. The primary end-points were the inci-
dence and severity of CRS and NEs. CRS was defined and
graded per modified Lee 2014 criteria.11 NEs were identified
by specific search strategy per Topp et al14 and graded for
severity per Common Terminology Criteria for Adverse
Events version 4.03.15 Secondary end-points included
investigator-assessed ORR (CR plus partial response) per
revised International Working Group Response Criteria for
Malignant Lymphoma,16 duration of response (DOR),
progression-free survival (PFS), overall survival (OS), inci-
dence of AEs and levels of anti-CD19 CAR-T cells and
cytokines in blood (Data S1). Confidence intervals (CIs) for
ORRs were generated by the Clopper-Pearson method, and
CIs and landmark estimates of DOR, PFS and OS were gen-
erated by Kaplan–Meier (KM) survival method. For patients
who underwent SCT before documented progression, DOR
and PFS were censored at SCT date. Exploratory end-points
included biomarker assessments (Data S1).
The modified intent-to-treat (mITT) population, compris-
ing all enrolled patients treated with axi-cel at a dose of
≥1 9 106 CAR-T cells/kg, was used for response-based end-
points. All patients treated with any dose of axi-cel were
included in the safety analysis set. Tumour burden was mea-
sured by sum of product diameters of target lesions.16 For
patients who received bridging therapy (excluding corticos-
teroids alone), baseline tumour burden was measured after
bridging therapy, but before conditioning therapy.
Fig 1. Toxicity management in ZUMA-1. *Only in case of comorbidities or older age. †Only if no improvement with tocilizumab, use standard
dose. ‡If no improvement after 24 h. §If no improvement after three days. ||Only for grade 2 or higher NEs with concurrent CRS. AE, adverse
event; CRS, cytokine release syndrome; HD, high dose; Mgmt, management; NE, neurologic event. [Colour figure can be viewed at wileyonline
library.com]
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Propensity score matching (PSM) analysis
Exploratory retrospective PSM analysis17,18 was performed to
descriptively compare results for cohort 6 and cohorts 1 + 2
(primary analysis)4 after balancing for the following key base-
line disease characteristics: tumour burden, International
Prognostic Index score, number of prior lines of chemother-
apy, disease stage and lactate dehydrogenase level (Data S1).
Results
Patient disposition and baseline and product
characteristics
Beginning on 1 May 2019, 62 patients were screened; 42 were
enrolled and leukapheresed (Figure S1). Of 42 enrolled
patients, 40 (95%) received conditioning chemotherapy and
axi-cel. The manufacturing success rate was 98% (n = 41/42).
Two patients did not receive axi-cel due to product not
available and sponsor decision (n = 1 each). The 40 axi-cel-
treated patients comprised both the mITT and safety analysis
populations. Twenty-one patients (53%) received bridging
therapy before axi-cel, most commonly corticosteroids
(23%), bendamustine/rituximab plus corticosteroids (10%)
and bendamustine/rituximab alone (8%; Table SIII). Median
tumour burden was not significantly reduced with bridging
therapy. One patient did not receive corticosteroid prophy-
laxis per protocol on days 1 and 2 because of site error. The
data cut-off date was 16 June 2020; the median follow-up
was 8"9 months (range, 6"0–12"1 months).
The median patient age was 64"5 years (range, 37–
85 years); 65% of patients had stage III or IV disease, 38%
had three or more prior therapies and 43% had PD as best
response to most recent chemotherapy (Table I). Pre-
infusion product characteristics (total number of T cells, per
cent transduction, IFN-c production and T-cell phenotypes)
are shown in Table SIV.
Safety
AEs occurred in all treated patients. The most frequent any-
grade AEs were pyrexia (85%), hypotension (55%) and neu-
tropenia (50%; Table II). Grade 3 or higher AEs were
reported in all treated patients — the most frequent were
neutropenia (45%), neutrophil count decreased (33%), anae-
mia (20%) and white blood cell count decreased (20%).
Three patients (8%) had fatal treatment-emergent AEs: one
respiratory failure due to ongoing respiratory infection (day
91; related to axi-cel), one urosepsis (day 107; unrelated to
axi-cel) and one unknown AE, identified per public records
that occurred after the patient withdrew consent to undergo
autologous SCT. Prolonged grade 3 or higher cytopenias pre-
sent on or after day 30 post-axi-cel infusion were reported in
18 patients (45%): neutropenia (30%; 0% febrile), thrombo-
cytopenia (20%) and anaemia (10%; Table SV). Overall,
50% of patients experienced infections, with median time to
onset of 42"5 days (range, 3–219 days) post-axi-cel infusion;
20% of patients had grade 3 or higher infections.
CRS occurred in 32 patients (80%); all cases were grade 1
or 2 (Table III). The most common CRS symptoms among
patients with CRS were pyrexia (97%), hypotension (53%)
and hypoxia (19%). Median time to CRS onset was 5"0 days
(range, 1–15 days); median duration was 4"0 days (range, 1–
11 days). All CRS-related events had resolved by the data
cut-off.
Twenty-three patients (58%) experienced NEs, including
three patients (8%) with worst-grade 3 NEs and two patients
(5%) with worst-grade 4 NEs. The most frequent any-grade
NE symptoms among patients with NEs were confusional
state (38%), tremor (23%) and aphasia and somnolence
(each 15%). Among grade 3 or higher NEs, the most
Table I. Patient and disease characteristics at baseline.
Characteristic Cohort 6 (n = 40)
Age
Median (range), years 64"5 (37–85)
≥65 years, n (%) 20 (50)
Male sex, n (%) 23 (58)
ECOG performance status score of 1, n (%) 22 (55)
Disease stage, n (%)
I or II 14 (35)
III or IV 26 (65)
IPI score, n (%)
0–2 22 (55)
3–4 18 (45)






Prior autologous SCT, n (%) 10 (25)
PD as best response to most
recent chemotherapy, n (%)*
17 (43)
Median (range) tumour
burden by SPD,† mm2
1 184 (116–17 057)
Median (range) LDH, U/l 236 (155–2 042)
Median (range) ferritin, ng/ml 364 (13–1 748)
Refractory subgroup, n (%)
Primary refractory 2 (5)
Refractory ≥ second-line therapy 23 (58)
Relapsed ≥ second-line therapy 7 (18)
Relapsed post-ASCT 8 (20)
ASCT, autologous stem cell transplant; ECOG, Eastern Cooperative
Oncology Group; IPI, International Prognostic Index; LDH, lactate
dehydrogenase; PD, progressive disease; SCT, stem cell transplant;
SPD, sum of the products of diameters.
*For patients who had not relapsed post-ASCT.
†Restaged after bridging, except for two patients without post-
bridging assessment in which case the screening assessments were
used for baseline.
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common symptoms among patients were seizure (8%; two of
three patients were receiving levetiracetam prophylaxis at the
time) and mental status change (5%). Median time to NE
onset was 6"0 days (range, 2–162 days); median duration was
18"5 days (range, 1–103 days). At data cut-off, NEs had
resolved in 20 of 23 patients (Table SVI). Notably, 68% of
patients (n = 27/40) did not experience either NEs or CRS
within 72 h (days 0–3) of axi-cel infusion.
Excluding prophylaxis, corticosteroids were used to treat
CRS, NEs and other events in 17 patients (43%), 16 patients
(40%) and 1 (3%) patient respectively. The median cumula-
tive cortisone-equivalent corticosteroid dose required to treat
CRS or NEs was 1 878 mg (n = 24), with median time to
onset of 5"0 days (range, 3–9 days) post-infusion. The med-
ian cumulative cortisone-equivalent corticosteroid dose was
1 252 mg including prophylaxis (n = 40) and 2 504 mg
excluding prophylaxis (n = 25; Table SVII). As 15 patients
received corticosteroids only as prophylaxis and no addi-
tional corticosteroids for AE management, the median cumu-
lative dose shifted to a smaller value when prophylactic doses
were included versus excluded. Tocilizumab (≥1 dose) was
used to treat CRS in 23 patients (58%) and NE with concur-
rent grade 2 CRS in one patient (3%).
Efficacy
The investigator-assessed ORR was 95% (95% CI, 83–99%),
and the CR rate was 80% (95% CI, 64–91%; Fig 2A). ORR and
CR rates were 100% and 73%, respectively, in the 15 patients
who received corticosteroid prophylaxis only and were 92%
and 84%, respectively, in the 25 patients who received corti-
costeroids for prophylaxis and toxicity management.
Median DOR [KM DOR median follow-up, 5"8 months
(95% CI, 5"1–8"0 months)] was not reached; the KM esti-
mate of the six-month DOR rate was 62"4% (95% CI, 41"6–
77"6%; Fig 2B). As of the data cut-off date, 62"5% of treated
patients remained in ongoing response. Median PFS and OS
were not reached (Figure S2). KM estimates of the six-
month PFS and OS rates were 72"2% (95% CI, 54"1–84"1%)
and 87"3% (95% CI, 72"1–94"5%) respectively. One patient
proceeded to SCT post-axi-cel.
Biomarker analyses
Median peak CAR-T cell expansion was observed within
2 weeks post-axi-cel infusion (64"4 cells/µl blood; Fig 3A).
Table II. Treatment-emergent adverse events of any grade occurring
in ≥15% of patients and grade 3 or higher adverse events occurring
in >10% of patients.





Any 40 (100) 10 (25) 26 (65)
Pyrexia 34 (85) 5 (13) 0
Hypotension 22 (55) 5 (13) 0
Neutropenia 20 (50) 3 (8) 15 (38)
Fatigue 18 (45) 1 (3) 0
Confusional state 15 (38) 1 (3) 0
Constipation 15 (38) 0 0
Nausea 14 (35) 1 (3) 0
Anaemia 13 (33) 8 (20) 0
Headache 13 (33) 0 0
Neutrophil count decreased 13 (33) 4 (10) 9 (23)
Diarrhoea 11 (28) 1 (3) 0
Hypokalaemia 11 (28) 2 (5) 0
Hypophosphataemia 11 (28) 6 (15) 0
Thrombocytopenia 10 (25) 5 (13) 2 (5)
Tremor 9 (23) 1 (3) 0
Chills 8 (20) 0 0
Decreased appetite 8 (20) 0 0
Hypoxia 8 (20) 2 (5) 1 (3)
Vomiting 8 (20) 1 (3) 0
White blood cell count decreased 8 (20) 2 (5) 6 (15)
Arthralgia 7 (18) 0 0
Dyspnoea 7 (18) 1 (3) 0
Leukopenia 7 (18) 1 (3) 5 (13)
Aphasia 6 (15) 1 (3) 0
Cough 6 (15) 0 0
Dizziness 6 (15) 0 0
Hypogammaglobulinaemia 6 (15) 0 0
Hyponatraemia 6 (15) 2 (5) 0
Insomnia 6 (15) 0 0
Muscular weakness 6 (15) 1 (3) 0
Platelet count decreased 6 (15) 0 4 (10)
Somnolence 6 (15) 0 0
Tachycardia 6 (15) 1 (3) 0
Table III. Incidence, severity, onset, and duration of CRS and NEs.
TEAE Cohort 6 (n = 40)
CRS
Any, n (%) 32 (80)
Worst grade 1, n (%) 14 (35)
Worst grade 2, n (%) 18 (45)
Worst grade 3, n (%) 0
Worst grade 4, n (%) 0
Worst grade 5, n (%) 0
Median (range) time to
onset of any-grade CRS, days
5"0 (1–15)
Median (range) duration, days 4"0 (1–11)
Neurologic events
Any, n (%) 23 (58)
Worst grade 1, n (%) 10 (25)
Worst grade 2, n (%) 8 (20)
Worst grade 3, n (%) 3 (8)
Worst grade 4, n (%) 2 (5)
Worst grade 5, n (%) 0
Median (range) time to onset
of any-grade NE, days
6"0 (2–162)
Median (range) duration, days 18"5 (1–103)
CRS, cytokine release syndrome; NE, neurologic event; TEAE,
treatment-emergent adverse event.
O. O. Oluwole et al.
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Median levels of inflammatory serum biomarkers previously
shown to be associated with severe NEs and/or CRS4 — such
as IFN-c, IL-2, GM-CSF, and ferritin — peaked within
8 days post-axi-cel infusion (Fig 3B).
PSM analysis
The incidence of grade 3 or higher CRS and grade 3 or
higher NEs observed in cohort 6 (0% and 13% respectively)
was numerically lower compared with cohorts 1 + 2 (13%
and 28% respectively).4 However, cohort 6 was not
designed to provide statistical comparison with cohorts
1 + 2, and the patients in these cohorts were not balanced
with respect to key baseline characteristics. To verify the
primary analysis findings, PSM was performed using known
predictive and prognostic markers for clinical outcomes in
LBCL and with CAR-T cell therapy (cohorts 1 + 2 and
other studies).4,9,19–21 Standardised mean difference18,22 val-
ues demonstrated that covariates were appropriately bal-
anced after PSM (Table SVIII). Baseline disease
characteristics were comparable between 32 matched
patients each in cohort 6 and cohorts 1 + 2 (Table SIX).
Eight patients in cohort 6 were excluded due to non-
availability of matched patients in cohorts 1 + 2 using a
caliper criterion during PSM. Efficacy and safety outcomes,
CAR-T cell levels and soluble serum biomarkers are sum-
marised in Table SX. Differences in incidence of grade 3 or
higher CRS and time to onset of CRS observed between
patients in cohorts 1 + 2 and cohort 6 before PSM were
maintained after PSM. The incidence, severity and onset of
NEs were generally similar between cohort 6 and cohorts
1 + 2 following PSM. Clinical efficacy (ongoing response
rates) in cohort 6 remained comparable to that observed in
cohorts 1 + 2 before and after PSM and was corroborated
by lower levels of soluble inflammatory biomarkers and
comparable peak CAR-T cell levels versus those in cohorts
1 + 2 before and after PSM. The median cumulative
cortisone-equivalent corticosteroid dose required to manage
CRS or NEs was lower in cohort 6 (1878 mg) than in
matched cohorts 1 + 2 (7418 mg).
Fig 2. (A) Objective response rates (ORRs) and (B) duration of response (DOR) in patients achieving an objective response in ZUMA-1 cohort
6. For patients who underwent stem cell transplantation before documented progression, DOR was censored at the date of stem cell transplanta-
tion. CR, complete response; NE, not estimable; NR, not reported; PR, partial response; SD, stable disease. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Discussion
Optimal CRS and NE management in patients treated with
CAR-T cell therapy remains a subject of ongoing
research,5,6,8,23,24 and the effects of corticosteroid use on out-
comes remain unclear in retrospective analyses.25,26 Relative
to the initial management scheme used in ZUMA-1 cohorts
1 + 2,3,4 ZUMA-1 cohort 4 explored earlier corticosteroid
Fig 3. Levels of (A) blood chimaeric antigen receptor (CAR)-T cells and (B) key soluble serum biomarkers over time. Dashed lines (A) and bars
(B) represent the interquartile range. BL, baseline; CRP, C-reactive protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN,
interferon; IL, interleukin; MCP-1, monocyte chemoattractant protein 1.
O. O. Oluwole et al.
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and/or tocilizumab intervention.13 The present cohort 6
study investigated the effects of prophylactic corticosteroid
use and early corticosteroid and/or tocilizumab intervention
on the incidence of CRS and NEs in patients with R/R
LBCL.
In the absence of randomised data, the cohort 6 results sug-
gest that prophylactic corticosteroids and early corticosteroid
and/or tocilizumab intervention may benefit axi-cel-treated
patients. Foremost, incidence rates of grade 3 or higher CRS
were 13%, 2% and 0% in cohorts 1 + 2, 4 and 6 respec-
tively.4,13 The fact that no cases of grade 3 or higher CRS
occurred among patients treated with prophylactic corticos-
teroids is encouraging, as is the progressively shorter median
CRS duration (8, 7 and 4 days, in cohorts 1 + 2, 4 and 6
respectively) and delayed time to CRS onset (median 2, 2 and
5 days, in cohorts 1 + 2, 4 and 6 respectively).4,13 Moreover,
the incidence of grade 3 or higher NEs in cohort 6 (13%) was
comparable to that of cohort 4 (17%), and both rates were
numerically lower than in cohorts 1 + 2 (28%). However, the
median duration of NEs in cohort 6 was numerically longer
than that previously reported in cohorts 4 and 1 + 2 (18"5, 8
and 13 days respectively). Of note, n =27/40 patients (68%) in
cohort 6 did not experience either CRS or NEs within 72 h
(days 0–3) of axi-cel infusion; these results pave the way for
optimisation of corticosteroid utilisation, which may increase
the proportion of patients that can be managed in an outpa-
tient setting early post-axi-cel infusion.
Corticosteroid prophylaxis and early corticosteroid and/or
tocilizumab intervention did not appear to compromise axi-
cel efficacy. At a median study follow-up of 8"9 months, the
ORR (95%) and CR rates (80%) were higher than corre-
sponding rates in the primary analyses of cohorts 1 + 2
(82% and 54% respectively4) or 4 (73% and 51% respec-
tively13). With longer follow-up for cohorts 1 + 2 (median
27"1 months), the ORR was 83%, the CR rate was 58%, the
median PFS was 5"9 months, and the median OS had not yet
been reached.3 In a subsequent follow-up (median
51"1 months) analysis, median OS was 25"8 months and the
KM estimate of the four-year OS rate was 44%.27 Additional
follow-up of cohort 6 patients will confirm if prophylactic
corticosteroids improve long-term safety without compro-
mising durability of responses.
Notably, prolonged use of high-dose corticosteroids for
NE treatment is hypothesised to affect CAR-T cell expansion
and therefore clinical outcomes of treated patients.28
Although glucocorticoids induce lymphocyte apoptosis,29 and
immunosuppressive agents may diminish CAR-T cell expan-
sion,30 no negative impact of corticosteroids on CAR-T cell
pharmacokinetics was noted in this study. However, the
lower levels of soluble biomarkers, including inflammatory
cytokines, observed in cohort 6 versus cohorts 1 + 2 suggest
that systemic corticosteroids may exert an immunomodula-
tory effect that reduces immune cell-related inflammation
more than CAR-T cell expansion.31 Notably, the median
cumulative cortisone-equivalent corticosteroid dose required
to treat CRS or NEs was numerically lower in cohort 6
(1878 mg) versus cohorts 1 + 2 (7418 mg). Overall, prophy-
lactic corticosteroids and earlier corticosteroid and/or tocili-
zumab intervention resulted in a lower cumulative
corticosteroid dose (overall and to treat CRS or NEs) with-
out negatively affecting CAR-T cell pharmacokinetics or effi-
cacy (ongoing response rates).
Because the safety management cohorts were not designed
or powered for statistical comparisons with each other or
with the pivotal cohorts, differences in baseline characteristics
and cohort sizes should be considered when making compar-
isons. To overcome these limitations and reduce bias in the
absence of a randomised trial, PSM17,18 was applied to
cohorts 1 + 2 and cohort 6. This statistical method adjusts
for potential imbalances in baseline disease characteristics
between cohorts, thereby providing a more balanced and
robust comparison.18,32 The aforementioned differences in
CRS toxicity outcomes observed between patients in cohort 6
and cohorts 1 + 2 before and after PSM, together with gen-
erally similar NE toxicity after PSM, suggest a benefit of early
AE intervention and corticosteroid prophylaxis. Furthermore,
response rates in cohort 6 were comparable to those
observed in cohorts 1 + 2 before and after PSM and were
corroborated by CAR-T cell pharmacokinetics.
In summary, the use of prophylactic corticosteroids and
earlier corticosteroid and/or tocilizumab intervention for tox-
icity management resulted in no cases of grade 3 or higher
CRS, delayed CRS onset, and generally similar NE toxicity
without adversely affecting CAR-T cell pharmacokinetics or
efficacy outcomes for axi-cel-treated patients.
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